Treatment of small intestinal neuroendocrine tumors: Is an extended multimodal approach justified?

World Journal of Surgery

Volumn 26, Issue 8, 2002, Pages 976-984

  Schindl, Martin ^a   Kaczirek, Klaus ^a   Passler, Christian ^a   Kaserer, Klaus ^a   Prager, Gerhard ^a   Scheuba, Christian ^a   Raderer, Markus ^a   Niederle, Bruno ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; FLUOROURACIL; OCTREOTIDE; RECOMBINANT ALPHA2B INTERFERON; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN;

ADULT; AGED; ALOPECIA; CLINICAL FEATURE; CONFERENCE PAPER; DIARRHEA; FEMALE; FLU LIKE SYNDROME; HUMAN; INTESTINE STENOSIS; LIFE EXPECTANCY; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; NEUROENDOCRINE TUMOR; QUALITY OF LIFE; SMALL INTESTINE; SMALL INTESTINE TUMOR; SURVIVAL; VOMITING; ARTICLE; ARTIFICIAL EMBOLISM; CARCINOID; EVALUATION; INTESTINE TUMOR; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; COMBINED MODALITY THERAPY; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036691527     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00268-002-6628-6     Document Type: Conference Paper

References (60)

1. Oberndorfer S. Karzinoid Tumore des Dünndarms. Frankf. Z. Pathol. 1907;1:426-430
2. Buchanan KD, Johnston CF, O'Hare MM, et al. Neuroendocrine tumors: a European view. Am. J. Med. 1986;81:14-22
3. Gehan EA, Tefft MC. Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J. Natl. Cancer Inst. 2000;92:179-181
4. Kusaba H, Saijo N. [A summary report of response evaluation criteria in solid tumors (RECIST criteria)]. Gan To Kagaku Ryoho 2000;27:1-5
5. Sasaki T. [New guidelines to evaluate the response to treatment "RECIST."]. Gan To Kagaku Ryoho 2000;27:2179-2184
6. Agranovich AL, Anderson GH, Manji M, et al. Carcinoid tumour of the gastrointestinal tract: prognostic factors and disease outcome. J. Surg. Oncol. 1991;47:45-52
7. Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Digestion 1994;55:11-23
8. Onaitis MW, Kirshbom PM, Hayward TZ, et al. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann. Surg. 2000;232:549-556
9. Rindi G, Capella C, Solcia E. Cell biology, clinicopathological profile, and classification of gastro-enteropancreatic endocrine tumors. J. Mol. Med. 1998;76:413-420
10. Soreide JA, van Heerden JA, Thompson GB, et al. Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J. Surg. 2000;24:1431-1436
11. McDermott EW, Guduric B, Brennan MF. Prognostic variables in patients with gastrointestinal carcinoid tumours. Br. J. Surg. 1994;81:1007-1009
12. Shebani KO, Souba WW, Finkelstein DM, et al. Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann. Surg. 1999;229:815-821
13. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J. Surg. 1990;14:377-383
14. Soreide O, Berstad T, Bakka A, et al. Surgical treatment as a principle in patients with advanced abdominal carcinoid tumors. Surgery 1992;111:48-54
15. Steele G Jr, Ravikumar TS. Resection of hepatic metastases from colorectal cancer: biologic perspective. Ann. Surg. 1989;210:127-138
16. Jadallah F, McCall JL, van Rij AM. Recurrence and survival after potentially curative surgery for colorectal cancer. N.Z. Med. J. 1999;112:248-250
17. Janson ET, Holmberg L, Stridsberg M, et al. Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann. Oncol. 1997;8:685-690
18. Wichmann MW. Gender differences in long-term survival of patients with colorectal cancer. Br. J. Surg. 2001;88:1092-1098
19. Makridis C, Ekbom A, Bring J, et al. Survival and daily physical activity in patients treated for advanced midgut carcinoid tumors. Surgery 1997;122:1075-1082
20. Ahlman H, Wangberg B, Jansson S, et al. Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion 2000;62:59-68
21. Ahlman H. The role of surgery in patients with advanced midgut carcinoid tumours. Digestion 1996;57:86-87
22. Akerstrom G, Makridis C, Johansson H. Abdominal surgery in patients with midgut carcinoid tumors. Acta Oncol. 1991;30:547-553
23. Nave H, Mossinger E, Feist H, et al. Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery 2001;129:170-175
24. Ahlman H, Westberg G, Wangberg B, et al. Treatment of liver metastases of carcinoid tumors. World J. Surg. 1996;20:196-202
25. Wangberg B, Nilsson O, Tylen U, et al. Interventional treatment of carcinoid tumors of the small bowel and the colon. Chir. Gastroenterol. 1997;13:292-297
26. Que FG, Nagorney DM, Batts KP, et al. Hepatic resection for metastatic neuroendocrine carcinomas. Am. J. Surg. 1995;169:36-42
27. Grazi GL, Cescon M, Pierangeli F, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 2000;47:481-486
28. Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J. Am. Coll. Surg. 2000;190:432-445
29. McEntee GP, Nagorney DM, Kvols LK, et al. Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 1990;108:1091-1096
30. Norton JA. Surgical management of carcinoid tumors: role of debulking and surgery for patients with advanced disease. Digestion 1994;55:98-103
31. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion 2000;62:92-97
32. Oberg K. Neuroendocrine gastrointestinal tumors - a condensed overview of diagnosis and treatment. Ann. Oncol. 1999;10 (Suppl 2):S3-8
33. Oberg K. Carcinoid tumors: current concepts in diagnosis and treatment. Oncologist. 1998;3:339-345
34. Oberg K. Advances in chemotherapy and biotherapy of endocrine tumors. Curr. Opin. Oncol. 1998;10:58-65
35. Oberg K. Endocrine tumors of the gastrointestinal tract: systemic treatment. Anticancer Drugs 1994;5:503-519
36. Oberg K, Alm G, Magnusson A, et al. Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J. Natl. Cancer Inst. 1989;81:531-535
37. Skinazi F, Zins M, Menu Y, et al. Liver metastases of digestive endocrine tumours: natural history and response to medical treatment. Eur. J. Gastroenterol. Hepatol. 1996;8:673-678
38. Moertel CG, Rubin J, Kvols LK. Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon. J. Clin. Oncol. 1989;7:865-868
39. Lequaglie C, Patriarca C, Cataldo I, et al. Prognosis of resected well-differentiated neuroendocrine carcinoma of the lung. Chest 1991;100:1053-1056
40. Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion 2000;62:84-91
41. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut 1996;38:430-438
42. Bartsch HH, Stockmann F, Arnold R. Treatment of patients with metastatic carcinoid tumors by recombinant human interferon-alpha: results from a phase II study. J. Cancer Res. Clin. Oncol. 1990;116:305
43. Eriksson B, Renstrup J, Imam H, et al. High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects. Ann. Oncol. 1997;8:1041-1044
44. Eriksson BK, Larsson EG, Skogseid BM, et al. Liver embolizations of patients with malignant neuroendocrine gastrointestinal tumors. Cancer 1998;83:2293-2301
45. Janson ET, Ronnblom L, Ahlstrom H, et al. Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial. Ann. Oncol. 1992;3:635-638
46. Mantke R, Ridwelski K, Manger T, et al. [Multimodal therapy concept in metastatic carcinoid of the gastrointestinal tract.]. Langenbecks Arch. Chir. Suppl. Kongressbd. 1997;114:1101-1104
47. Ruszniewski P, Malka D. Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 2000;62:79-83
48. Siperstein AE, Rogers SJ, Hansen PD, et al. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery 1997;122:1147-1154
49. Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J. Surg. 2001;25:693-696
50. Seifert JK, Cozzi PJ, Morris DL. Cryotherapy for neuroendocrine liver metastases. Semin. Surg. Oncol. 1998;14:175-183
51. Bilchik AJ, Sarantou T, Foshag LJ, et al. Cryosurgical palliation of metastatic neuroendocrine tumors resistant to conventional therapy. Surgery 1997;122:1040-1047
52. Giovannini M, Seitz JF. Ultrasound-guided percutaneous alcohol injection of small liver metastases: results in 40 patients. Cancer 1994;73:294-297
53. Johnson LB, Krebs T, Wong-You-Cheong J, et al. Cryosurgical debulking of unresectable liver metastases for palliation of carcinoid syndrome. Surgery 1997;121:468-470
54. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J. Vasc. Interv. Radiol. 1999;10:397-403
55. Winkelbauer FW, Niederle B, Pietschmann F, et al. Hepatic artery embolotherapy of hepatic metastases from carcinoid tumors: value of using a mixture of cyanoacrylate and ethiodized oil. A.J.R. Am. J. Roentgenol. 1995;165:323-327
56. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 1993;189:541-547
57. Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am. J. Clin. Oncol. 2000;23:412-415
58. O'Toole D, Ducreux M, Bommelaer G, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer 2000;88:770-776
59. Faiss S, Rath U, Mansmann U, et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion 1999;60:469-476
60. Di Bartolomeo M. Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group. Cancer 1996;77:402-408